This study examined the association between patient characteristics and patient-reported outcomes for patients prescribed specialty medications from rheumatology or multiple sclerosis clinics in two HSSPs for 3,677 patients over 30 months. Patients reporting tolerability issues or lower perceived effectiveness were more likely to report a missed dose.

We implemented a standardized documentation tool (SmartForms) that would collect discrete data fields during the specialty pharmacist's workflow in Dermatology clinic. This allowed us to collect data for reporting purposes on the front end, save time, document pharmacist interventions prior to treatment initiation, improve Epic documentation visibility and future usability.

This study evaluated patient-reported outcomes (PROs) and pharmacist interventions in patients serviced by VSP in various clinical conditions. In patients with MS specifically, we found that 98% of patients reported no adverse effects, 90% reported no missed doses, and 98% reported their medication worked "good" or "excellent." Pharmacist interventions were commonly related to adherence, safety monitoring, and adverse effects. PROs can be useful to drive meaningful pharmacist interventions.

Patients initiated on vesicular monoamine transport 2 inhibitor (VMAT2i) therapy for Tourette Syndrome and chronic tic disorders had a 50% discontinuation rate within the first 12-months of therapy. Patient reported adverse events were the main driver for discontinuation with most events being reported within 100 days of VMAT2i initiation. Further studies exploring persistence rates of VMAT2i therapy in the setting of common comorbid conditions are needed within this population.

Patient reported outcomes can be used to measure therapeutic response, as well as overall health status, functioning, quality of life, and disease management. Patients with inflammatory conditions who fill medication within an integrated HSSP model reported low rates of missed doses and side effects, and most rated high perceived medication effectiveness.

Patient reported outcomes (PROs) are used to assess response to medication and the need for therapeutic adjustments in patients with rheumatologic disease states. Vanderbilt Specialty Pharmacy, an integrated health-system specialty pharmacy, assesses PROs through monthly refill questionnaires to guide specialty pharmacist interventions and improve patient care.

The objective of this study was to characterize the HCV cascade of care in a bridge clinic setting and identify barriers to HCV treatment in this population. This study demonstrated that several challenges and barriers exist to engage patients in HCV care in a bridge clinic model, and more strategies should be identified to engage patients and link them to care.

This study evaluated the rate and reasons for Primary Medication Nonadherence (PMN) to specialty oral oncology medications in Health System Specialty Pharmacies (HSSP). Multisite retrospective cohort study across 7 HSSP sites. Most patients (89%) prescribed oral oncology treatment at HSSP initiated therapy. Primary medication nonadherence was mostly due to patient decision.

The goal of this study was to explore healthcare providers’ experiences with specialty medications distributed via Limited Distribution Networks (LDN) that do not include IHSSPs. Participants reported barriers to navigating LDNs that can interfere with clinic workflow and patient care. IHSSPs may reduce clinic burden by helping patients access, afford, and remain on therapy.